MeMed has raised $ 93 million in favor of commercializing the technology to differentiate between diseases from bacteria or viruses

MeMed’s solution enables an informed decision whether to treat antibiotics or not and thus supports the fight against bacterial resistance to antibiotics The investment will be used To accelerate additional product development and global marketing and expansion

ערן עדן וכפיר עובד מי-מד באדיבות מי-מד
Eran Eden and Kfir work as a water meter courtesy of the water meter

The Israeli company MeMed announces today (Monday) that it has completed a $ 93 million round of funding, an investment that brings the total investment in the company to over $ 200 million (including grants from the US Army and the European Union). The investment will be used to accelerate the development of additional products for diagnosing the immune system response, expanding production, commercialization and global expansion.

MeMed, which specializes in diagnosing the host-response, has recently received regulatory approval (K510). ) From the U.S. Food and Drug Administration (FDA), to the U.S. marketing of the MeMed BV test, a test that helps clinicians distinguish between viral infections and bacterial infections, and of the – MeMed Key A groundbreaking platform for measuring a large number of proteins simultaneously, in a few minutes and with a high level of accuracy . The test has been approved for use in children and adults. MeMed has also developed the COVID-19 Severity בדיק test, which is able to predict deterioration in the health of Corona patients, which has been approved for marketing in Europe and Israel.

Horizon Ventures, Shavit Capital Fund, Caesarea Medical Holdings, Union Tech Ventures, Clal Insurance, Phoenix, Bank Hapoalim, Social Capital Fund, Touchwood Capital Fund, La Maison Partners, WTI and other investors.

MeMed BV Tests a protein signature based on the immune system response, developed and validated over a decade of collaborations With leading academic and commercial partners. It provides physicians with an essential tool for distinguishing between bacterial and viral infections and for answering this key clinical question with sensitivity and specificity of over 90% (NPV> 98%), regardless of the type of pathogen, the onset of symptoms, or the presence of harmless microorganisms.

    MeMed BV measures and weights using a computational algorithm the levels of three Proteins that participate in the immune system response: TRAIL, IP-10, and CRP. The test is performed on a serum sample using the MeMed Key® and provides a result within 15 minutes.

    MeMed BV has been validated in many international clinical trials Conducted in double-blind, and published after peer review in leading journals (including Pediatrics , The Lancet ID , PLOS One , BMJ Peds , and the European Journal of Clinical Microbiology & Infectious Diseases), as well as data collected from more than 15,000 patients as part of their hospital care routine.

    MeMed BV Approved for marketing in Europe (CE Mark) and Israel (AMR).

    “The investment will enable MeMed to accelerate its technological development and expand globally with an emphasis on the American market,” he said Dr. Eran Aden, CEO and co-founder of MeMed . The FDA we have received, as well as our expanding network of relationships and partnerships, in order to provide patients with access to our advanced technologies, alongside the continued development of additional pioneering products in the field of response diagnosis from Immune Kit

    Patrick Zang , The Horizon Ventures Fund added: “We believe that MeMed’s strategy, which includes developing products to decipher the immune system response, is a significant advantage in improving two major areas that occupy modern medicine today: bacterial resistance to antibiotics and effective patient care. Corona. We welcome the partnership with MeMed – the category leader in this field and are proud to take part in the journey and how it improves the way patients around the world can be diagnosed and treated ”

    More on this topic On the knowledge site:

    MeMed Israel has received FDA approval to market technology for distinguishing between pollution Viral Bacteria MeMed has been recognized as a “technological pioneer” By the World Economic Forum ) Research Committee at the Bureau The Chief Scientist has approved 16 research and development programs within the framework of the R&D Fund, with an investment of NIS 35.5 million Identify patterns in the ancient soup from which life was created A state-of-the-art rapid corona test thanks to a sugar molecule

    Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

    Related Posts
    US drone-Russian jet collision swirls in debate. What happened? thumbnail

    US drone-Russian jet collision swirls in debate. What happened?

    When a Russian fighter jet collided with a large U.S. surveillance drone over the Black Sea on Tuesday, it was a rare but serious incident that triggered a U.S. diplomatic protest and raised concerns about the possibility Russia could recover sensitive technology.United States and Russian officials had conflicting accounts of the collision between the MQ-9
    Read More
    We Asked a NASA Scientist: Are Wildfires Getting Worse? [Video] thumbnail

    We Asked a NASA Scientist: Are Wildfires Getting Worse? [Video]

    The Camp Fire wildfire in 2018 burned a total of 239 square miles, destroyed 18,804 structures and killed 85 people. Researchers say it also produced lingering brain trauma in some of those exposed to the deadliest and most destructive wildfire in California history. Credit: National Institute of Standards and TechnologyAre wildfires getting worse?Yes, unfortunately, they
    Read More
    To start the week off right, eco-efficient processes, hydrogen and printed electronics thumbnail

    To start the week off right, eco-efficient processes, hydrogen and printed electronics

    Industrie et Technologies Publié le 27/09/2021à 10h00 Soyez le premier à réagir Sairem, qui commercialise des procédés industriels par micro-onde, a présenté sa technologie et ses recherches lors du congrès d'ALLICE, le 21 septembre. Ici un équipement de vulcanisation du caoutchouc. © Sairem Trois procédés innovants ont été mis en lumière lors du premier congrès…
    Read More
    3D printing: the not so distant dream of the distributed factory thumbnail

    3D printing: the not so distant dream of the distributed factory

    Alexandre Couto Publié le 04/01/2022à 14h00 Soyez le premier à réagir Les spécialistes de la fabrication additive proposent aux industriels des micro-usines modulaires pour accompagner leur demande de flexibilité et leur permettre une production connectée et distribuée, au plus près des usages. Une production plus flexible, réalisée le plus près possible du lieu d’utilisation. Ce…
    Read More
    Index Of News
    Consider making some contribution to keep us going. We are donation based team who works to bring the best content to the readers. Every donation matters.
    Donate Now

    Subscription Form

    Liking our Index Of News so far? Would you like to subscribe to receive news updates daily?

    Total
    0
    Share